Michael Rodrigues, MD
Otolaryngology · Bel Air, MDNPI 1043304348
Payments from drug & device makers
Across 80 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$708
- Optinose US, Inc.$361
- Sanofi$314
- Regeneron Healthcare Solutions, Inc.$251
- Smith+Nephew$77
- Sanofi-aventis U.S. LLC$53
- plus $147 from 6 others
What the payments were for
- Food & beverage$1,85997%
- Education$533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $708 |
| Optinose US, Inc. | 17 | $361 |
| Sanofi | 15 | $314 |
| Regeneron Healthcare Solutions, Inc. | 9 | $251 |
| Smith+Nephew | 3 | $77 |
| Sanofi-aventis U.S. LLC | 1 | $53 |
| Intersect ENT, Inc. | 1 | $52 |
| Baxter Healthcare | 1 | $29 |
| Stryker | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Alk-abello, Inc | 1 | $13 |
How this compares
$1,912 in reported general payments places this provider in the 60th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $82,879 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 44 | $5,540 |
| Fluticasone Propionate | 184 | $2,617 |
| Azelastine Hcl | 50 | $1,993 |
| Fluocinolone Acetonide Oil | 49 | $1,817 |
| Omeprazole | 78 | $1,797 |
| Ipratropium Bromide | 23 | $1,198 |
| Montelukast Sodium | 86 | $939 |
| Levothyroxine Sodium | 25 | $682 |
| Mometasone Furoate | 11 | $676 |
| Ofloxacin | 19 | $557 |
| Meclizine Hcl | 38 | $553 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $335 |
| Famotidine | 20 | $245 |
| Nystatin | 16 | $230 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Bel Air
- Joshua LevyBethesda$873K
- Jean KimBaltimore$613K
- Douglas RehLutherville Timonium$561K
- Wojciech MydlarzBethesda$534K
- Carole FakhryBaltimore$502K
- Seth OringherChevy Chase$429K
- Nyall LondonBaltimore$367K
- Marc DubinBaltimore$350K
- Charles della SantinaBaltimore$297K
- Alexander HillelBaltimore$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.